Cargando…
Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapy
In the muscle invasive bladder cancer (MIBC) standard of care treatment only patients presenting a major pathological tumor response are more likely to show the established modest 5% absolute survival benefit at 5 years after cisplatin-based neoadjuvant chemotherapy (NAC). To overcome the drawbacks...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011207/ https://www.ncbi.nlm.nih.gov/pubmed/32049187 http://dx.doi.org/10.1590/s0102-865020190120000007 |